

Lars Norgren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8172885/publications.pdf>

Version: 2024-02-01

42
papers

3,088
citations

361413

20
h-index

302126

39
g-index

43
all docs

43
docs citations

43
times ranked

4276
citing authors

#	ARTICLE	IF	CITATIONS
1	Measurement and Interpretation of the Ankle-Brachial Index. <i>Circulation</i> , 2012, 126, 2890-2909.	1.6	1,232
2	Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. <i>New England Journal of Medicine</i> , 2017, 376, 32-40.	27.0	494
3	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries. <i>Journal of Endovascular Therapy</i> , 2015, 22, 663-677.	1.5	152
4	A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization. <i>Circulation</i> , 2017, 135, 2534-2555.	1.6	136
5	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). <i>Vascular Medicine</i> , 2015, 20, 465-478.	1.5	127
6	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). <i>Annals of Vascular Diseases</i> , 2015, 8, 343-357.	0.5	122
7	Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. <i>Circulation</i> , 2017, 135, 241-250.	1.6	111
8	Acute Limb Ischemia in Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 556-565.	1.6	80
9	An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee*. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 611-625.	1.7	76
10	Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease. <i>JAMA Network Open</i> , 2018, 1, e185239.	5.9	68
11	Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3274-3284.	2.8	64
12	Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. <i>American Heart Journal</i> , 2016, 175, 86-93.	2.7	41
13	Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1563-1572.	2.8	39
14	PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 57, 538-545.	1.5	33
15	Stroke in Patients With Peripheral Artery Disease. <i>Stroke</i> , 2019, 50, 1356-1363.	2.0	33
16	Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 608-617.	2.8	30
17	Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2018, 23, 523-530.	1.5	29
18	Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 55, 109-117.	1.5	28

#	ARTICLE	IF	CITATIONS
19	Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2019, 4, 7.	6.1	26
20	Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006399.	2.2	23
21	Intraperitoneal Metabolic Consequences of Supraceliac Aortic Balloon Occlusion in an Experimental Animal Study Using Microdialysis. <i>Annals of Vascular Surgery</i> , 2014, 28, 1286-1295.	0.9	21
22	Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006512.	2.2	16
23	Prioritization of treatments for lower extremity peripheral artery disease in low- and middle-income countries. <i>International Angiology</i> , 2017, 36, 203-215.	0.9	13
24	Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. <i>Vascular Medicine</i> , 2019, 24, 422-430.	1.5	13
25	Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. <i>Journal of the American Heart Association</i> , 2021, 10, e018684.	3.7	13
26	Intra-abdominal Hypertension—An Experimental Study of Early Effects on Intra-abdominal Metabolism. <i>Annals of Vascular Surgery</i> , 2015, 29, 128-137.	0.9	11
27	Cause of Death Among Patients With Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006550.	2.2	10
28	Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. <i>American Heart Journal</i> , 2020, 220, 51-58.	2.7	8
29	Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009326.	3.9	7
30	Impact of Procedural Bleeding in Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008069.	3.9	6
31	Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. <i>International Journal of COPD</i> , 2021, Volume 16, 841-851.	2.3	6
32	Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	4
33	Metabolic Response to Claudication in Peripheral Arterial Disease: A Microdialysis Pilot Study. <i>Annals of Vascular Surgery</i> , 2019, 58, 134-141.	0.9	3
34	Perioperative intraperitoneal metabolic markers in patients undergoing cardiac surgery with cardiopulmonary bypass: an exploratory pilot study. <i>Perfusion (United Kingdom)</i> , 2019, 34, 552-560.	1.0	2
35	CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. <i>American Heart Journal</i> , 2020, 229, 118-120.	2.7	2
36	Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009871.	3.9	2

#	ARTICLE	IF	CITATIONS
37	Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. <i>Journal of Vascular Surgery</i> , 2022, 75, 660-670.e3.	1.1	2
38	World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2021, , 1358863X2110386.	1.5	2
39	Understanding Study Drug Discontinuation Through EUCLID. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	2
40	The Vascunet Report on Amputations: Does it Contribute?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 56, 400.	1.5	1
41	Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2021, 26, 1358863X2110176.	1.5	0
42	Peripheral artery disease and depression: Prerequisites for a lose-lose situation?. <i>Atherosclerosis</i> , 2021, 329, 30-31.	0.8	0